ABSTRACT
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of unknown etiology characterized by irreversible cognitive and physical deterioration. It has become more common not only in developed nations but also in developing countries as now the population includes more and more old persons. Though exact cause for the disease isn't known, it is closely related to the formation of protein deposits (amyloid plaques) and tangled bundles of fibres (neurofibrillary tangles) within the cortex (1) . The 'amyloid cascade theory' proposes that longer form of Amyloid β (Aβ), mainly Aβ 1-42 is particularly pathogenic that spontaneously self-aggregates into amyloid fibrils that are somehow neurotoxic and cause dementia. However, the factors that facilitate Aβ accumulation and how this relates to dementia have remained contentious (2) . Various studies have implicated that the toxicity of Aβ is due to abnormal interaction of trace metals zinc, copper and iron in neocortex (3) (4) (5) .
Zinc, copper and iron are constitutively found at high concentration in the neocortical regions, most prone to AD pathology, where they play important role in normal physiology. However, iron and copper can catalyse Fenton's reactions, generating a flux of reactive oxygen species that can damage functional and structural macromolecules. Various studies done so far supporting the role of copper in AD are in vitro studies. Very few in vivo studies have been carried out so far. In vitro studies show that Aβ catalyses H 2 O 2 generation through the reduction of cupric (Cu 2+ ) and ferric (Fe 3+ ), using O 2 and biological reducing agents like vitamin C, cholesterol as substrates (6) (7) (8) . The neurotoxicity of Aβ is mediated by release of H 2 O 2 which is freely permeable to the tissue membrane. If not scavenged by antioxidant enzymes like catalase and glutathione peroxidase, it reacts with reduced metal ions (Fe 2+ , Cu + ) to generate hydroxyl ion (OH•) which is toxic to neurons. Aβ has high affinity for copper and is not toxic in the absence of it (6) . The neurotoxic role of copper is further supported by studies done in animal models (9, 10) . These studies show that amyloid plaque seen in AD has high affinity for copper. Copper homeostasis imbalance and excessive oxidative stress in brain tissue leading to it's accumulation in senile plaques and neurofibrillary tangles are documented in AD (11) .
In vivo studies demonstrate that elevated serum copper levels differentiate patients with AD from age matched normal individuals with good selectivity and specificity (12) . According to the above studies serum copper concentration may be a potential marker for AD. Hence, studies of the systemic levels of copper in patients of AD which are reported rarely in literature are of increasing interest.
It is still debatable, whether raised copper levels contribute to pathogenesis or is an effect of the disease. In circulation, 70% copper is tightly bound to ceruloplasmin (13) . The rest of copper is distributed among transcuprein, albumin and amino acids. Copper is principally eliminated by bile (> 95%) and only 3% is eliminated by urinary excretion (14) . Elevated copper levels could be due to failure of liver to clear copper in old age. It is therefore, relevant to do clinical studies of liver functions in AD to determine the origin of serum copper. Ceruloplasmin, a α 2 globulin functioning as a copper transporter, is a marker of both plasma copper status and inflammation (15, 16) . Hence, it is important to show ceruloplasmin-copper relationship to interpret the raised copper levels in AD in vivo studies.
To assess the role of copper as peripheral marker, we studied serum copper levels in AD. In this study, we also estimated serum ceruloplasmin to verify whether excess of serum copper is related to ceruloplasmin in AD. Further, to identify that these changes are specific to patients with AD, we compared these levels of copper and ceruloplasmin in vascular dementia patients. In the present study, the attempt has been made to assess liver function status as well in AD.
MATERIALS AND METHODS
Fifty AD patients (mean age 60 years), fifty cognitive normal individuals (mean age 55 years) and twenty four patients with vascular dementia (Mean age 59 years) were included in the study. The groups were matched for sex and age. The AD patient's sample consisted of individuals with a diagnosis of probable AD (National Institute of Neurological and Communicable Diseases and Stroke/AD Related Disorders Association Criteria) (17) who had a Mini-Mental state Examination (MMSE) score of < 25. All patients underwent neurologic, neuroimaging (MRI) and extensive neuropsychological examination along with routine laboratory tests. The Vascular Dementia (VaD) patients were selected on the basis of clinical history and brain MRI showing microangiopathic pathology.
The control samples consisted of elderly individuals attending the hospital with ailment other than cognitive impairment and coming to clinics routinely for other neurological disease. All patients with recent history of heart or respiratory failure, chronic liver or renal failure, malignant tumors and recent history of alcohol abuse were excluded from test and control group. Also subjects having conditions known to affect copper metabolism were excluded from the study.
All participants underwent assays of copper, ceruloplasmin and liver enzymes along with routine laboratory tests.
Biochemical investigations:
Blood was collected from patients as routine sample taking all standard precautions. Serum was separated with in 30 min. and rapidly stored at -80°C. Serum copper concentration was measured by colorimetric method without deproteinisation using 4-(3, 5-Dibromo-2-pyridylazo)-N-ethyl-N-sulfopropylaniline (18) . Serum ceruloplasmin was assayed by turbidimetric specific reaction using ceruloplasmin polyclonal antiserum (19) .
Cognitive Evaluation: The Alzheimer's disease has clinical features including memory impairment, disturbances of visuospatial, language abnormalities and executive function deficits. Cognitive evaluation was done by neuropsycological testing with standardised assessment, which provides a mean of quantifying the deficits of AD. The MMSE (mini-mental status examination) is the most widely used mental status questionnaire. It includes 30 questions assessing orientation, learning, attention, serial subtraction, recall, naming, repetition, comprehension, reading and writing. It is generally insensitive to the cognitive abnormalities present in the earliest phases of AD. Therefore a detailed mental status examination is mandatory. The detached mental status examination is directed to test all the lobar functions like language, praxis, agnosia, abstraction, calculation etc. ADScog scale is used to monitor the patient's progression or improvement accordingly.
Neuroimaging: Neuroimaging is mandatory for diagnosing the dementia. Generalised atrophy is seen in all patients of Alzheimer's disease with selective temporoparietal atrophy. FMRI is a better modality in diagnosing the early cases of Alzheimer's disease.
Statistical Analysis: AD and VaD patients were compared for age, sex and cognitive characterstics with control and each other. To assess the levels of serum copper and ceruloplasmin in differentiating patients with AD, VaD and healthy subjects, one way analysis of variance (ANOVA) has been applied and multiple comparision test-Student-Newman-Keuls (SNK) method has also been applied when results of ANOVA showed significant difference.
RESULTS
One way analysis of variance (ANOVA) has been applied to compare the average value of age, serum copper and ceruloplasmin and multiple comparision test StudentNewman-Keuls (SNK) method has also been applied to explain which group is actually significantly different from others when results of ANOVA showed significant difference. Table 1 shows the demographic features in patients with AD, VaD and controls. Patients and controls were age matched, the mean age of patients with AD was 59.96 ± 11.57 years which was comparable to mean age in VaD (58.79 ± 12.53 years) and was slightly higher as compared to controls (55.32 ± 10.88 years). The groups differed and did not match for sex in AD and VaD. The proportion of women in AD (38 %) was higher as compared to VaD (39%) and controls (34 %). AD and VaD groups differed for MMSE score (14.07 vs16.76). Table 2 summaries the data of age, copper and ceruloplasmin in patients with AD, VaD and controls. There was no significant difference in mean age in all the patients of AD, VaD and controls. However, ANOVA result show that mean value of serum copper and ceruloplasmin were significantly different among AD, VaD and controls (p= 0.002 and p < 0.001 respectively). The mean value of copper in AD and VaD were significantly raised compared to controls (p= 0.001 and p= 0.04 respectively) as shown by multiple comparision analysis done by SNK method. However, ceruloplasmin levels observed in patients with AD were significantly higher as compared to VaD (p< 0.001) and controls (p < 0.001). Serum ceruloplasmin levels were also significantly raised in VaD as compared to controls (p= 0.019).
In women, the serum copper levels were raised significantly in both AD and VaD (p= 0.008 and p= 0.009 respectively) as compared to controls as shown in Table 3 . However, ceruloplasmin levels were significantly raised only in AD (p= 0.002). Table 4 shows copper and ceruloplasmin values in three groups among males. Serum copper levels were significantly raised in patients with AD as compared to controls (p= 0.042) whereas ceruloplasmin levels were again significantly higher in AD as compared to VaD and controls (p= 0.001 and p= 0.003 respectively). Among patients with AD and VaD, it was observed that the difference in copper levels wasn't significant (p= 0.38). However, ceruloplasmin levels were significantly lower in patients with VaD as compared to AD (p= 0.001). Table 5 shows gender wise comparison of all three studied variables i.e age, copper and ceruloplasmin levels within each patients group (AD, VaD and controls). Student's 't' test was applied and none of the variables were found significantly associated with gender in any of the studied groups.
To establish the copper-ceruloplasmin relationship in serum, Pearson product moment correlation was applied. In AD and VaD patients, there was weak correlation between serum copper and ceruloplasmin (r= 0.21 in AD and r= 0.38 in VaD). Similar observation was made in control.
DISCUSSION
The present study shows that serum copper, a peripheral marker of oxidative stress and trace metals can discriminate between AD patients and controls. The serum copper levels were significantly raised (p= 0.001) in patients with AD as compared to controls. There was 16.4 % increase in serum copper levels in AD patients. In vivo studies done in AD patients show altered peripheral copper metabolism along with raised copper in serum (20) (21) (22) . There is one study which is not in line with our finding and has not shown similar results (23) . Neurodegeneration in AD by copper induced toxicity is mediated by it's binding to Amyloid β(Aβ) protein leading to high metal-ion-to-peptide stoichiometry, Aβ aggregates and becomes catalytically pro-oxidant. These changes appear at high serum copper concentration as reported by Ashley et al (2) . Amyloid β protein is generated from amyloid precursor protein (APP). Aβ possess copper and zinc binding sites. A β 1-42 has high affinity for copper which could trap excess extra cellular copper and prevents it from adversely participating in radical generating activity (24, 25) . At a high peptide to metalion stoichiometry, A β removes the copper into the circulation and is protective. This may explain the present finding that serum copper is selectively and markedly elevated in individuals. However, at high metal-ion-to peptide stoichiometry, Aβ, on being catalytically pro-oxidant, leads to simultaneous generation of H 2 O 2 , making the peptide vulnerable to OH • attack (7) . The raised copper levels in AD may be explained by the reported deficiency of metallothionein in brain tissue. Metal ions in the brain are handled by number of proteins and transport system, metallothionein being one of the examples of former. Studies show disturbances in handling of metal ions in the brain due to the deficiency of these proteins in AD patients. Failure of incorporation of metal ions in the metallothionein system could contribute to pooling of metal ions in the extra cellular space and contributes to the Aβ precipitation. Further, numerous abnormalities of blood brain barrier reported in individuals with AD may further contribute to fluctuating levels of plasma ions (26, 27) .
To assess whether serum copper elevation is specific to AD and is not secondary to neurodegeneration, or as part of inflammatory process, serum copper levels were also measured in patients with vascular dementia. Our findings show that serum copper levels were significantly elevated in VaD as compared to controls. However, the raised serum copper levels were seen in both AD and VaD in women but in men raised serum copper were observed in AD only with no change in VaD as compared to controls. Our current findings are not in concurrence with the previous reports. Studies done by Squitti et al (12) shows raised serum copper levels in AD as compared to VaD. The raised serum copper seen in AD and VaD in the present study may signify that raised copper in AD is due to disturbed copper metabolism but secondary to oxidative stress seen as part of neurodegeneration occurring in AD and VaD. It is important to point out here that it is too early to come to this conclusion and further studies should be carried out with larger subject size. Also, more studies should be carried out in male subjects to ensure whether serum copper can be used in male subjects as biomarker for diagnosis of AD and in differential diagnosis of AD from VaD.
In the body, 90 % copper is bound to ceruloplasmin which is synthesized by liver and majority of copper is excreted in bile. Hence, in the present study, serum ceruloplasmin was also measured to find out whether raised copper levels can be explained by ceruloplasmin status in serum. The present study shows that serum ceruloplasmin levels were significantly raised in AD as well as VaD as compared to controls. However, increase in serum ceruloplasmin was more so in AD as compared to VaD. The raised copper levels in AD and VaD observed in the present study may be explained by raised ceruloplasmin levels in these patients. Same kind of pattern was observed in men and women. In women, significant increase in serum ceruloplasmin was observed in AD and VaD patients, more in AD as compared to VaD. However, in men, AD patients had raised serum ceruloplasmin levels as compared to controls but no such change in serum ceruloplasmin was observed in VaD as compared to controls. Only one study has been cited in which levels of ceruloplasmin were measured along with serum copper in the patients with AD and VaD (4) . In this study, no significant change was observed in serum ceruloplasmin levels in AD and VaD patients as compared to controls. Further studies are required to explain our findings.
Our main finding is that copper discriminates patients with AD from controls but not from VaD. The probable existence in AD of an excess of copper might play a role in Aβ-mediated toxicity to the brain by virtue of its pro-oxidant property. Hence, raised copper levels are also found in VaD. The limitation of present study was small sample size, especially in VaD. Also, the serum copper levels should be studied in other neurodegenerative disorders. Presently studies are under way in which copper levels are evaluated to discriminate AD from Parkinson's disease. Our department is also involved in such study.
